Evolving role of entrectinib in treatment of NTRK-positive tumors.

Abstract	Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with NTRK fusion positive solid tumors and ROS1 positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated.
Authors	Neal Chawla, Nam Q Bui, Mahesh Seetharam
Journal	Future oncology (London, England) (Future Oncol) Vol. 17 Issue 22 Pg. 2835-2846 (Aug 2021) ISSN: 1744-8301 [Electronic] England
PMID	33896226 (Publication Type: Journal Article, Review)
Chemical References	Benzamides Indazoles Membrane Glycoproteins NTRK1 protein, human NTRK3 protein, human Oncogene Proteins, Fusion Protein Kinase Inhibitors Pyrazoles Pyrimidines Receptor, trkA Receptor, trkB Receptor, trkC tropomyosin-related kinase-B, human entrectinib larotrectinib
Topics	Animals Benzamides (pharmacology, therapeutic use) Cell Line, Tumor Clinical Trials as Topic Disease Models, Animal Drug Approval Drug Evaluation, Preclinical Humans Indazoles (pharmacology, therapeutic use) Membrane Glycoproteins (antagonists & inhibitors, genetics) Molecular Targeted Therapy (methods, trends) Neoplasms (drug therapy, genetics, mortality, pathology) Oncogene Proteins, Fusion (antagonists & inhibitors, genetics) Progression-Free Survival Protein Kinase Inhibitors (pharmacology, therapeutic use) Pyrazoles (pharmacology, therapeutic use) Pyrimidines (pharmacology, therapeutic use) Receptor, trkA (antagonists & inhibitors, genetics) Receptor, trkB (antagonists & inhibitors, genetics) Receptor, trkC (antagonists & inhibitors, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!